Role of testosterone in regulating induction of TNF-α in rat spleen via ERK signaling pathway

Steroids ◽  
2016 ◽  
Vol 111 ◽  
pp. 148-154 ◽  
Author(s):  
Chien-Wei Chen ◽  
Cai-Yun Jian ◽  
Po-Han Lin ◽  
Chih-Chieh Chen ◽  
Fu-Kong Lieu ◽  
...  
2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Bao Zhu ◽  
Lulu Zhang ◽  
Chun Liang ◽  
Bin Liu ◽  
Xiangbin Pan ◽  
...  

Aging is a risk factor for cardiovascular disease, and there is no effective therapeutic approach to alleviate this condition. NF-κB and TNF-α have been implicated in the activation of the aging process, but the signaling molecules responsible for the inactivation of NF-κB and TNF-α remain unknown. Exosomes have been reported to improve heart functions by releasing miRNA. Recent studies suggest that lncRNAs are more tissue-specific and developmental stage-specific compared to miRNA. However, the role of lncRNA in exosome-mediated cardiac repair has not been explored. In the present study, we focused on metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), which is an lncRNA associated with cell senescence. We discovered that human umbilical cord mesenchymal stem cell- (UMSC-) derived exosomes prevent aging-induced cardiac dysfunction. Silencer RNA against lncRNA MALAT1 blocked the beneficial effects of exosomes. In summary, we discovered that UMSC-derived exosomes prevent aging-induced cardiac dysfunction by releasing novel lncRNA MALAT1, which in turn inhibits the NF-κB/TNF-α signaling pathway. These findings will lead to the development of therapies that delay aging and progression of age-related diseases.


Placenta ◽  
2021 ◽  
Vol 103 ◽  
pp. 16-23
Author(s):  
Guangzhuang Jing ◽  
Jianling Yao ◽  
Yuhui Dang ◽  
Weitao Liang ◽  
Li'ao Xie ◽  
...  

2016 ◽  
Vol 83 ◽  
pp. 1335-1344 ◽  
Author(s):  
Bo Li ◽  
Ru-Yin Hu ◽  
Li Sun ◽  
Rui Luo ◽  
Kai-Hang Lu ◽  
...  

2014 ◽  
Vol 15 (5) ◽  
pp. 535-549 ◽  
Author(s):  
Ji-Yeun Park ◽  
Jongbae J. Park ◽  
Songhee Jeon ◽  
Ah-Reum Doo ◽  
Seung-Nam Kim ◽  
...  

2019 ◽  
Author(s):  
Yue Zhang ◽  
Xiaowei Ding ◽  
Changhong Miao ◽  
Jiawei Chen

Abstract Purpose: The levels of tight junction proteins (TJs), especially occludin, correlate with blood-brain barrier (BBB) disruption caused by inflammation in central nervous system (CNS). It has been reported that propofol, the most commonly used anesthetic, could inhibit inflammation response in CNS. In this study, we investigated the effects of tumor necrosis factor-α(TNF-α) and propofol on occludin expression in human cerebral microvascular endothelial cell line, D3 clone (hCMEC/D3 cells), and explored the underlying mechanisms. Methods: The hCMEC/D3 cells were treated with propofol, followed by TNF-α. The expression and phosphorylation of Hif-1α, VEGF, VEGFR-2, ERK, p38MAPK and occludin were measured by Western blot analysis. The cell viability of hCMEC/D3 cells was measured by cell counting kit-8. Results: TNF-α (10 ng/ml, 4 h) significantly decreased the expression of occludin, which was attenuated by propofol (25 μM). TNF-α induced Hif-1α/VEGF/VEGFR-2/ERK signaling pathway, while propofol could inhibit it. TNF-α induced the phosphorylation of p38MAPK, while propofol had no effect on it. In addition, the inhibitors of Hif-1α, VEGF, VEGFR-2, and ERK could reduce the effect of TNF-α on occludin expression. Conclusion: TNF-α could decrease the expression of occludin via activating Hif-1α/VEGF/VEGFR-2/ERK signaling pathway, which was attenuated by propofol.


2021 ◽  
Vol 21 ◽  
Author(s):  
Mehran Pashirzad ◽  
Reihaneh Khorasanian ◽  
Maryam Mahmoudi Fard ◽  
Mohammad-Hassan Arjmand ◽  
Hadis Langari ◽  
...  

: The MAPK/ERK signaling pathway regulates cancer cell proliferation, apoptosis, inflammation, angiogenesis, metastasis and drug resistance. Mutations and up-regulation of components of the MAPK/ERK signaling pathway, as well as over-activation of this critical signaling pathway, are frequently observed in colorectal carcinomas. Targeting the MAPK/ERK signaling pathway, using specific pharmacological inhibitors, elicits potent anti-tumor effects, supporting the therapeutic potential of these inhibitors in the treatment of CRC. Several drugs have recently been developed for the inhibition of the MEK/ERK pathway in preclinical and clinical settings, such as MEK162 and MK-2206. MEK1/2 inhibitors demonstrate promising efficacy and anticancer activity for the treatment of this malignancy. This review summarizes the current knowledge on the role of the MAPK/ERK signaling pathway in the pathogenesis of CRC and the potential clinical value of synthetic inhibitors of this pathway in preventing CRC progression for a better understanding, and hence, better management of colorectal cancer.


2013 ◽  
Vol 89 (3) ◽  
pp. 199-208 ◽  
Author(s):  
LS Nikitina ◽  
NA Dorofeeva ◽  
OD Kirillova ◽  
AA Korotkov ◽  
M Glazova ◽  
...  

Gene Reports ◽  
2016 ◽  
Vol 3 ◽  
pp. 1-4 ◽  
Author(s):  
Nilüfer Erkasap ◽  
Rumeysa Özyurt ◽  
Mete Özkurt ◽  
Fatih Yaşar ◽  
Serdar Erkasap ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document